OmnicellOMCL
Market Cap: $2.08B
About: Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
Employees: 3,590
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
369% more call options, than puts
Call options by funds: $4.23M | Put options by funds: $901K
13% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 85
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.33% less ownership
Funds ownership: 101.29% [Q1] → 100.96% (-0.33%) [Q2]
8% less capital invested
Capital invested by funds: $1.37B [Q1] → $1.25B (-$116M) [Q2]
9% less funds holding
Funds holding: 265 [Q1] → 240 (-25) [Q2]
48% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 52
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
JP Morgan Anne Samuel 40% 1-year accuracy 2 / 5 met price target | 18%downside $37 | Neutral Maintained | 23 Aug 2024 |
Wells Fargo Stan Berenshteyn 60% 1-year accuracy 3 / 5 met price target | 34%downside $30 | Equal-Weight Maintained | 2 Aug 2024 |
B of A Securities Allen Lutz 63% 1-year accuracy 5 / 8 met price target | 3%downside $44 | Buy Maintained | 2 Aug 2024 |
Barclays Stephanie Davis 83% 1-year accuracy 5 / 6 met price target | 36%downside $29 | Equal-Weight Upgraded | 2 Aug 2024 |
Benchmark Bill Sutherland 65% 1-year accuracy 24 / 37 met price target | 16%downside $38 | Buy Reiterated | 15 Jul 2024 |
Financial journalist opinion
Based on 4 articles about OMCL published over the past 30 days